ResMed concluded fiscal year 2025 with a robust fourth quarter, driven by strong global demand for sleep and breathing health devices and an expanding digital health ecosystem. The company achieved double-digit revenue growth and significant improvements in gross margin and earnings per share.
Revenue increased by 10% to $1.348 billion in Q4 2025, demonstrating strong market demand.
Non-GAAP gross margin improved by 230 basis points to 61.4%, reflecting enhanced efficiencies.
Diluted earnings per share (EPS) grew by 30% to $2.58, while non-GAAP diluted EPS increased by 23% to $2.55.
Operating cash flow for the quarter was strong at $539 million, significantly exceeding net income.
ResMed plans to continue investing in innovation, scaling digital health capabilities, and partnering with stakeholders to expand access to care in fiscal year 2026.
Visualization of income flow from segment revenue to net income